Period of time： 2013年12期
Publisher： Springer Publishing Company
Founded in： 1990
Total resources： 9
ISSN： 0923-7534
Subject： R73 Oncology
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Annals of Oncology,volume 12,issue 12
Menu
Access to resources
Recommend
By Rubin I.,Yarden Y. in (2001)
Annals of Oncology,volume 12,issue 12 , Vol. 12, Iss. 12, 2001-12 , pp.The role of overexpressed HER2 in transformation
By Neve R.M.,Lane H.A.,Hynes N.E. in (2001)
Annals of Oncology,volume 12,issue 12 , Vol. 12, Iss. 12, 2001-12 , pp.By Ménard S.,Casalini P.,Campiglio M.,Pupa S.,Agresti R.,Tagliabue E. in (2001)
Annals of Oncology,volume 12,issue 12 , Vol. 12, Iss. 12, 2001-12 , pp.Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling
By Lane H.A.,Motoyama A.B.,Beuvink I.,Hynes N.E. in (2001)
Annals of Oncology,volume 12,issue 12 , Vol. 12, Iss. 12, 2001-12 , pp.HER2 as a prognostic and predictive marker for breast cancer
By Cooke T.,Reeves J.,Lanigan A.,Stanton P. in (2001)
Annals of Oncology,volume 12,issue 12 , Vol. 12, Iss. 12, 2001-12 , pp.HER2 status: A statistician’s view
Annals of Oncology,volume 12,issue 12 , Vol. 12, Iss. 12, 2001-12 , pp.Mechanism of action of anti-HER2 monoclonal antibodies
By Baselga J.,Albanell J. in (2001)
Annals of Oncology,volume 12,issue 12 , Vol. 12, Iss. 12, 2001-12 , pp.Pharmacologic insights into the future of trastuzumab
By Leyland-Jones B.,Arnold A.,Gelmon K.,Verma S., ,Seidman A.,Dias R.,Howell J.,Rakhit A. in (2001)
Annals of Oncology,volume 12,issue 12 , Vol. 12, Iss. 12, 2001-12 , pp.Phase I and II clinical trials of trastuzumab
Annals of Oncology,volume 12,issue 12 , Vol. 12, Iss. 12, 2001-12 , pp.
Previous
Next